Header Logo

Connection

MARINA KONOPLEVA to Everolimus

Back to Details
This is a "connection" page, showing publications MARINA KONOPLEVA has written about Everolimus.
MARINA KONOPLEVA
Connection Strength
0.103
Everolimus
  1. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 2007 Apr 15; 109(8):3509-12.
    View in: PubMed
    Score: 0.059
  2. PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Sci Rep. 2017 02 21; 7:43013.
    View in: PubMed
    Score: 0.030
  3. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006 Sep 01; 12(17):5165-73.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.